The mechanism of action of calcium antagonists relative to their clinical applications.

Abstract

As a class of therapeutic agents calcium antagonists have attracted increasing attention in recent years. Their major indications have been in the treatment of ischaemic myocardial syndromes, certain cardiac arrhythmias, hypertension, obstructive cardiomyopathies, and a number of lesser clinical disorders in which their role is less clearly defined. With the widening spectrum of therapeutic utility and an increasing plethora of newer agents under development, it is of importance to relate the overall pharmacodynamics of individual agents to their clinical effects. Calcium antagonists have a variable specificity for cardiac and peripheral activity. Based on such activity, it is useful to construct a classification of these compounds, new and old, into four categories. Type I agents, typified by verapamil and its congeners (tiapamil and gallopamil) and diltiazem, prolong AV nodal conduction and refractoriness with little effect on ventricular or atrial refractory period. These actions account for their direct antiarrhythmic properties. Type II agents include nifedipine and other dihydropyridines. In vivo, these agents are devoid of electrophysiologic effects in usual doses. They are potent peripheral vasodilators with some selectivity of action for different vascular beds; their overall haemodynamic effects are dominated by this peripheral vasodilatation and reflex augmentation of sympathetic reflexes. Type III agents include flunarizine and cinnarizine (piperazine derivatives), which, in vitro and in vivo, are potent dilators of peripheral vessels, with no corresponding calcium‐blocking actions in the heart. Type IV agents are agents with a broader pharmacologic profile (perhexiline, lidoflazine and bepridil); they block calcium fluxes in the heart, in the peripheral vessels, or both. They may inhibit the fast channel in the heart and have other electrophysiologic actions. A clear understanding of the varied pharmacologic properties of the different classes of calcium antagonists is likely to provide a rational basis for the use of these agents in clinical therapeutics.

Pharmacologic Treatment of Chronic Pediatric Hypertension

“…[80,81] Therefore, caution should be exercised (HR) and cardiac output that returns to pretreatment levels within a with the use of ACEIs in adolescent girls who have achieved few weeks of therapy. [86][87][88] Both GFR and renal plasma blood flow menarche. In addition, neurologic complications (i.e.…”

Twenty-Four-Hour Hemodynamic Effects of Two Different Dihydropyridine Derivatives Assessed by Noninvasive Methods in Patients with Congestive Heart Failure

“…According to the clinical classification of calcium an tagonists suggested by Singh [18], the dihydropyridines nitrendipine and felodipine both belong to those calcium channel blockers having predominantly vascular effects.…”

Update on the use of calcium antagonists on hypertension

“…2 Calcium entrance to the cells activates the contractile system in the smooth muscle and cardiac fibre; on the contrary, reduction in the amount of intracellular calcium tends to reduce myocardial contraction force, and peripheral and coronary vasodilation, a basic mechanism of the clinical usage in hypertension and as anti-angina agents. 3 Some calcium antagonists have the properties to impair the heart conductive system, mainly on the atria sinus and atria-ventricular nodes.…”